^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoScreen Plus®

    Company:
    Burning Rock Biotech
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    OncoScreen Plus® is a CE-marked, targeted next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP) panel developed by Burning Rock Biotech. It is designed for the qualitative detection of multiple types of somatic variants from formalin-fixed, paraffin-embedded (FFPE) tissue samples of patients with various solid tumors
    Cancer:
    Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Kidney Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Retinoblastoma, Skin Cancer, Solid Tumor, Thyroid Gland Carcinoma
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    05/07/22
    ST
    -
    CE